Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Prospective trial shows modest benefit of tamoxifen after adjuvant chemotherapy
April 6th, 2004
A long-running international trial of treating breast cancer patients with tamoxifen after adjuvant postoperative chemotherapy has shown that there seems to be a modest benefit. The researchers believe this is the first study that has confirmed prospectively what previously has been shown only in meta-analyses. Robert Paridaens, MD, a medical oncologist from the University Hospital Gasthuisberg in Leuven, Belgium, told the 4th European Breast Cancer Conference on March 17, 2004, that although adjuvant tamoxifen as a single therapy for patients with hormone receptor-positive operable breast cancer had been shown to reduce recurrence and death, its...
Source: Cancer Weekly (2004-04-06)
|
